QualityStocks would like to highlight TG Therapeutics, Inc. (OTCBB: TGTX), a development stage biopharmaceutical company, focused on the acquisition, development, and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company offers monoclonal antibodies for the treatment of various B-cell proliferative disorders, such as lymphoma, leukemia, and auto-immune diseases.
In the company’s news yesterday,
TG Therapeutics and Rhizen Pharmaceuticals S A announced their exclusive global agreement to co-develop and commercialize Rhizen’s lead product candidate, TGR-1202.
“We are excited to enter into this collaboration with Rhizen Pharmaceuticals, whose innovative pre-clinical development program has yielded an impressive portfolio of PI3K delta inhibitors that we are eager to advance into development,” Michael S. Weiss, executive chairman and Interim CEO of TG stated in the press release. “TGR-1202 has already demonstrated encouraging pre-clinical activity, and will serve to expand our pipeline as we seek to develop much needed therapies for patients suffering from hematologic malignancies.”
The companies will jointly develop the product on a worldwide basis (excluding India), with an initial focus on indications in the area of hematologic malignancies and autoimmune disease. Additionally, Rhizen will contribute backup molecules, creating several opportunities for TG to develop differentiated therapies against the aforementioned complications.
Rhizen will maintain rights to manufacture and supply the product to TG; TG will be responsible for all clinical and regulatory development for TGR-1202 globally.
The companies said they expect to file an IND for TGR-1202 by the end of 2012.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.